Day: March 8, 2021

Vancouver, B.C., March 08, 2021 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) (Lomiko or the “Company”) will be exhibiting at the 2021 Prospectors and Developers Association Conference (PDAC) from March 8 to 11, 2021.We invite conference delegates to visit us at our Virtual Booth in the Investors Exchange to discuss recent developments and plans for Lomiko’s La Loutre Graphite Project and the Electric Vehicle Zone (EV) area.  Lomiko is proud to be a member of the PDAC and official exhibitor in 2021.Electric Vehicle (EV) Zone Highlights The successful 2019 drilling campaign at the EV Zone (formerly Refractory) propelled Lomiko’s decision to consider metallurgy and a further study.  Please see the detailed EV Zone drill map for details. LL-16-01 – 7.74% Cg over 135.60 m including 16.81% Cg over 44.10...

LONDON, UNITED KINGDOM , March 08, 2021 (GLOBE NEWSWIRE) — Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF), the UK intellectual property investment group focused on creating valuable products from investing in university technology, announces that its portfolio company Belluscura plc has been granted 510(k) clearance and marketing authorisation by the U.S. Food and Drug Administration (FDA) for the X-PLO2R POC portable oxygen concentrator (POC). Belluscura developed the X-PLO2R POC with their research partner, Separation Design Group, an award-winning oxygen enrichment research laboratory. The X-PLO2R POC has patented technology that can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week. Weighing less than 3.25 lbs. (1.5 kg), the lightweight X-PLO2R POC is designed to replace larger, metal oxygen tanks and heavier...

DELRAY BEACH, Fla., March 08, 2021 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and Chief Executive Officer, will participate in a panel discussion during the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.The panel, entitled “Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away:  A discussion of various developmental therapeutics for SARS-CoV-2 infection,” is scheduled for March 15, 2021 from 12:00 to 1:00 p.m., ET. During the panel, Mr. Sapirstein will discuss the need for drug therapies to address issues related to COVID-19, including the prevalence of gastrointestinal symptoms...

MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro.“I am delighted to welcome Richard to the Baudax team and believe his expertise and leadership skills will be critically important to us as we continue to execute on the commercial rollout of ANJESO® in the U.S. and pursue our ongoing growth...

Note Holders Converted Notes into Equity, All Liens Have Been ReleasedCharlotte, N.C., March 08, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that both indentures associated with its Convertible Notes (as defined below) have been discharged and all associated liens have been released.As previously reported, the Company provided notices of redemption to holders of the Company’s 6.5% Convertible Senior Notes due 2023 (the “October 2018 Notes”) and to holders of the Company’s 6.5% Convertible Senior Secured Notes due 2023 (the “May 2018 Notes” and, together with the October 2018 Notes, the “Convertible Notes”) under the indentures...

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENTTHE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT.AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (“Mateon”) (OTCQB:MATN) announced today that it has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. Additionally, the targeted enrollment of the 18 patients of Part 1 has also been reached. The study was conducted through Oncotelic, Inc. (“Oncotelic”) – a wholly own subsidiary of Mateon.As explained in a prior press release, the trial is a multi-center, double blind, randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two (2) patient cohorts...

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences:Barclays Global Healthcare Conference on Thursday, March 11, 2021 from 11:30-11:55AM ETOppenheimer Virtual 31st Annual Healthcare Conference on Wednesday, March 17, 2021 from 1:10-1:40PM ETA live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.About Fate Therapeutics,...

BETHESDA, Md., March 08, 2021 (GLOBE NEWSWIRE) — Liquidity Services, Inc. (NASDAQ: LQDT; www.liquidityservices.com), the world’s largest B2B e-commerce marketplace for business and government surplus, announced today that its Board of Directors has authorized a new share repurchase program of up to $10,000,000 of the Company’s common stock. The repurchase program will commence today and expire on March 31, 2023. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and the existence of alternative investment opportunities. The repurchase program will be executed consistent with the Company’s capital allocation strategy of prioritizing investment to grow the business over the long term.Under the repurchase program, repurchases can be...

VIRGINIA CITY, Nev., March 08, 2021 (GLOBE NEWSWIRE) — Comstock Mining Inc. (the “Company”) (NYSE American: LODE), an emerging leader in climate-smart, sustainable mineral development and production, will host a conference call on Thursday, March 11, 2021 at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time to report its 2020 year end results and provide a business update. The Webcast will include a moderated Q&A, after the prepared remarks.  Please join the event 5-10 minutes prior to the scheduled start time. The link and/or dial-in telephone numbers for the live Webcast are as follows:Join Zoom Meetinghttps://us02web.zoom.us/j/7437013377Meeting ID: 743 701 3377One tap mobile+12532158782,,7437013377# US (Tacoma)+13462487799,,7437013377# US (Houston)Dial by your location+1 253 215 8782 US (Tacoma)+1 346 248 7799 US (Houston)+1...